CLEO Diagnostics LtdASX: COV

CLEO to Fast Track Development of Ovarian Cancer Test

· Issued by CLEO Diagnostics Ltd

Filed with ASX · · 4 pages · English

Summary by 6ix AI

CLEO Diagnostics Ltd has announced a collaboration with University College London to accelerate the development of its ovarian cancer test by accessing a significant number of high-quality blood samples from a major screening trial. This partnership aims to enhance CLEO's clinical validation program and support two clinical studies focused on pre-surgical and screening applications. The initiative is part of CLEO's broader strategy to deliver its ovarian cancer detection technology to the global market. The announcement highlights the potential impact of CLEO's technology in improving early detection and diagnosis of ovarian cancer.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

CLEO Diagnostics Ltd on 6ix

Earlier from CLEO Diagnostics

Later from CLEO Diagnostics

All CLEO Diagnostics news releases